Caidya and Simbec-Orion Combine to Create Integrated Specialty CRO From First-in-Human Through Registration
ICON Reports $3.3B in Gross Bookings and 1.42x Net Book-to-Bill in Q1 2026 as CRO Backlog Reaches $22.7B
Avance Clinical Expands CRO Footprint Into Singapore, Malaysia, and Mainland China to Build Six-Market Asia Pacific Platform Read more
Specialist CRO Engaged to Manage European Human Study Operations and Regulatory Submissions for Polyrizon’s NASARIX™ Allergy Blocker Read more
Pelago Bioscience Acquires RG Discovery to Deliver Fully Integrated Biology and Chemistry Drug Discovery CRO Platform Read more
FibroFind Appoints Co-Founder Lee Borthwick as CEO as Preclinical CRO Doubles in Size and Expands Leadership Team Read more
Sygnature Discovery and DaltonTx Collaborate to Advance AI-Enabled Decision-Making Across CRO Drug Discovery Programs Read more
Sapu Nano Appoints Global Clinical Trials as Lead CRO to Expand Sapu003 Phase 1b Program Into Europe Read more
Dr. Vince Clinical Research Strengthens Obesity CRO Credentials as Principal Investigator Earns ABOM Board Certification Read more
Creative Biostructure Partners With High Q Technologies to Bring Quantum EPR Spectroscopy to Structural Biology CRO Services Read more
Oxurion Terminates French CRO Acquisition and Pivots to International Multi-Region CRO Target Read more
Alpha Genesis Adds African Green Monkeys to NHP CRO Portfolio for Infectious Disease and Vaccine Research Read more
Perceptive Discovery and Certis Oncology Partner to Strengthen Translational Radiopharmaceutical CRO Development Read more
Syncell Launches Global Discovery CRO Service to Unlock Drug Targets With Nanoscopic Proteomics Read more
Momentum Biotechnologies Launches CHIPP Assay for Proteome-Wide, High-Throughput Drug Target Deconvolution Read more
InSphero Acquires CRO PhenoVista Biosciences to Strengthen U.S. Presence and High-Content Imaging Capabilities Read more
The US Reshoring Tide Goes Out: Record CDMO Newsflow, but the Investment Moved Back Offshore in H1 2026
C Ray Therapeutics Obtains First Category C Radiopharmaceutical Manufacturing License Under New NMPA Rules